Manager Community and Events, Healthcare Innovation - DayOne
Tel. +41 61 295 50 16thomas. brenzikofer@baselarea. swiss
In April, Ian Rentsch will take over as CEO of Clinerion, a Basel-based startup that runs a platform for recruiting patients for clinical trials. Rentsch sees major potential for Clinerion and will lead the startup’s global expansion.
Ian Rentsch will be Clinerion’s new CEO as of 1 April. Rentsch, who has a German-Argentinian background and is a lawyer and industrial business manager by training, brings more than 21 years of international experience in the pharmaceutical sector. He will take over from Ulf Claesson, who will remain on the board of directors.
Clinerion’s Patient Recruitment System (PRS) finds suitable candidates for clinical trials by aligning patient data from clinics, giving patients faster access to innovative treatments.
Rentsch sees major potential for a company like Clinerion. “The company’s focus on electronic health data and innovative technologies allows it to reimagine how clinical research is conducted,” Rensch said in a statement announcing his appointment.
According to Claesson, Clinerion is now well established and ready to expand further around the world. “We can now support international studies wherever they may have recruitment needs,” said Claesson, adding that “Rentsch is the right person to take the company to the next level of success”.